Skip to main content

Mild Cognitive Impairment (MCI)

6
Pipeline Programs
16
Companies
10
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 15 programs with unclassified modality

Competitive Landscape

15 companies ranked by most advanced pipeline stage

Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
EscitalopramPhase 41 trial
Active Trials
NCT01902004Completed115Est. Jan 2019
Prevail Therapeutics
1 program
1
DonanemabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT05108922Completed148Est. Sep 2023
Biocorp
BiocorpFrance - Issoire
2 programs
1
XPro1595Phase 21 trial
transcranial electric stimulationN/A1 trial
Active Trials
NCT07092839Completed15Est. Jul 2024
NCT05321498Withdrawn0Est. Oct 2023
INmune Bio
INmune BioFL - Boca Raton
1 program
1
XPro1595Phase 2
Neurim Pharmaceuticals
Neurim PharmaceuticalsIsrael - Tel Aviv
1 program
1
melatoninPhase 21 trial
Active Trials
NCT00544791Unknown50Est. Oct 2010
CuraSen Therapeutics
CuraSen TherapeuticsCA - San Carlos
1 program
1
CST-2032, matching placebo for CST-2032, CST-107Phase 11 trial
Active Trials
NCT05033912Withdrawn0Est. May 2022
Design Therapeutics
1 program
Insole and ankle deviceN/A1 trial
Active Trials
NCT07127133Not Yet Recruiting150Est. Aug 2027
Design Pharmaceuticals
1 program
Insole and ankle deviceN/A
Innovation Pharmaceuticals
1 program
RICORDO-DTxN/A1 trial
Active Trials
NCT06657274Recruiting60Est. Aug 2026
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
RICORDO-DTxN/A
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
RICORDO-DTxN/A
Soterix Medical
Soterix MedicalNJ - Woodbridge
1 program
Transcranial Alternating Current StimulationN/A1 trial
Active Trials
NCT06783283Recruiting20Est. Dec 2027
Sandoz
SandozAustria - Kundl
1 program
transcranial electric stimulationN/A
Novartis
NovartisBASEL, Switzerland
1 program
transcranial electric stimulationN/A
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
transcutaneous auricular vagus nerve stimulationN/A1 trial
Active Trials
NCT07424365Recruiting80Est. May 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Angeles TherapeuticsEscitalopram
Prevail TherapeuticsDonanemab
BiocorpXPro1595
Neurim Pharmaceuticalsmelatonin
CuraSen TherapeuticsCST-2032, matching placebo for CST-2032, CST-107
Design TherapeuticsInsole and ankle device
Colorado Therapeuticstranscutaneous auricular vagus nerve stimulation
Soterix MedicalTranscranial Alternating Current Stimulation
Innovation PharmaceuticalsRICORDO-DTx
Biocorptranscranial electric stimulation

Clinical Trials (10)

Total enrollment: 638 patients across 10 trials

NCT01902004Angeles TherapeuticsEscitalopram

Brain Aging and Treatment Response in Geriatric Depression

Start: Oct 2013Est. completion: Jan 2019115 patients
Phase 4Completed
NCT05108922Prevail TherapeuticsDonanemab

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Start: Nov 2021Est. completion: Sep 2023148 patients
Phase 3Completed
NCT05321498BiocorpXPro1595

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Start: Jun 2023Est. completion: Oct 20230
Phase 2Withdrawn
NCT00544791Neurim Pharmaceuticalsmelatonin

The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment

Start: Oct 2007Est. completion: Oct 201050 patients
Phase 2Unknown
NCT05033912CuraSen TherapeuticsCST-2032, matching placebo for CST-2032, CST-107

A Study of CST-2032 in Subjects With Cognitive Impairment

Start: Oct 2021Est. completion: May 20220
Phase 1Withdrawn
NCT07127133Design TherapeuticsInsole and ankle device

An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD)

Start: Aug 2026Est. completion: Aug 2027150 patients
N/ANot Yet Recruiting
NCT07424365Colorado Therapeuticstranscutaneous auricular vagus nerve stimulation

Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations

Start: May 2025Est. completion: May 202880 patients
N/ARecruiting
NCT06783283Soterix MedicalTranscranial Alternating Current Stimulation

TACS to Engage Theta-Gamma Coupling and Enhance Working Memory in Patients With MCI (tACS-MCI)

Start: Jan 2025Est. completion: Dec 202720 patients
N/ARecruiting
NCT06657274Innovation PharmaceuticalsRICORDO-DTx

EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069

Start: Dec 2024Est. completion: Aug 202660 patients
N/ARecruiting
NCT07092839Biocorptranscranial electric stimulation

Non-invasive Deep Brain Stimulation to Enhance Motor Skill Acquisition in Individuals With Mild Cognitive Impairment

Start: Jun 2021Est. completion: Jul 202415 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 638 patients
16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.